RxDoctor Payments DataLook up a doctor →

Valerie Goodwin, PA

Physician Assistant · Birmingham, ALNPI 1154829257

Payments from drug & device makers

$32,641in general payments, 2019–2025

Across 800 payments — averaging $40.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$12K
  • Merck$6K
  • Novo Nordisk$2K
  • Medtronic$2K
  • Lilly USA, LLC$2K
  • Bayer$1K
  • plus $8K from 35 others

What the payments were for

  • Travel & lodging$6,43230%
  • Food & beverage$14,68270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,641 in reported general payments places this provider in the 95th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$1,544
Medicare patients
11
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide200$253,557
OzempicSemaglutide105$159,580
JardianceEmpagliflozin91$108,204
EliquisApixaban84$64,003
TrulicityDulaglutide35$35,129
XareltoRivaroxaban23$25,626
JanuviaSitagliptin Phosphate32$25,207
LinzessLinaclotide23$24,104
KerendiaFinerenone18$24,103
JanumetSitagliptin Phos/Metformin Hcl26$22,236
Repatha SureclickEvolocumab23$21,796
Fiasp FlextouchInsulin Aspart (Niacinamide)14$15,807
EntrestoSacubitril/Valsartan13$14,276
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$14,068
Breo ElliptaFluticasone/Vilanterol18$13,569

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,585$288,686235 claims
Novo NordiskOzempic$2,055$159,580105 claims
Boehringer IngelheimJardiance$417$108,20491 claims
PfizerEliquis$772$64,00384 claims
MerckJanuvia, Janumet$6,211$47,44358 claims
AbbVieLinzess, Synthroid$1,003$26,93657 claims
Johnson & JohnsonXarelto$457$25,62623 claims
BayerKerendia$1,151$24,10318 claims
GSKBreo Ellipta, Incruse Ellipta$47$17,54529 claims
NovartisEntresto$239$14,27613 claims
Astellas Pharma US IncMyrbetriq$114$9,19915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →